Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
Activated forms of Ras family members are prevalent in many cancers where Ras mutants transduce signals essential for transformation, angiogenesis, invasion and metastasis. As a cancer progression model, we used NIH3T3 cells to explore the mechanism of Ras-induced tumorigenesis. Ras family mutants H-RasV12 and Rit79L strongly induced foci formation, while Rho family mutants RhoA-QL, Rac1-QL and Cdc42-QL were less effective. A comparison of downstream transcriptional targets of Ras and Rho family members using a 26 383 element cDNA microarray revealed that the osteopontin (OPN) gene exhibited the best correlation between magnitude of gene expression change and level of foci formation (r=0.96, P<0.001). In association with H-RasV12- and Rit79L-mediated transformation, foci secreted OPN protein and upregulated the OPN receptor CD44, suggesting the novel initiation of an aberrant OPN-CD44-Rac autocrine pathway. In support of this were the following observations. First, RGD-deficient OPN protein-binding activity was present in H-RasV12-transformed cells but not in control cells, and binding activity was inhibited by the CD44 blocking antibody. Second, foci formation, cell invasion and Rac activity were induced by H-RasV12 and inhibited by the CD44 blocking antibody. Third, foci formation by H-RasV12 was substantially reduced by a short interfering RNA (siRNA) specifically targeting OPN expression for knockdown. Fourth, H-RasV12-mediated transformation was not blocked by the GRGDS peptide, suggesting that OPN effects were not mediated by the integrins. Lastly, OPN knockdown affected the downstream expression of 160 '2nd tier' genes, and at least a subset of these genes appears to be involved in transformation. Indeed, four genes were selected for knockdown, each resulting in a disruption of foci formation and/or invasion. These results underscore the role of aberrant autocrine signaling and transcriptional networking during tumorigenesis.
Teramoto
Hidemi
H
Oral and Pharyngeal Cancer Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892-4330, USA.
Castellone
Maria Domenica
MD
Malek
Renae L
RL
Letwin
Noah
N
Frank
Bryan
B
Gutkind
J Silvio
JS
Lee
Norman H
NH
D016475:3T3 Cells; D000818:Animals; D001483:Base Sequence; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D015972:Gene Expression Regulation, Neoplastic; D017930:Genes, Reporter; D018960:Hyaluronan Receptors / Q000502:physiology*; D051379:Mice; D009154:Mutation; D009361:Neoplasm Invasiveness; D020411:Oligonucleotide Array Sequence Analysis; D016376:Oligonucleotides, Antisense; D053495:Osteopontin; D016133:Polymerase Chain Reaction; D034741:RNA, Small Interfering / Q000235:genetics; D017384:Sequence Deletion; D012795:Sialoglycoproteins / Q000235:genetics*; D014162:Transfection; D020830:rac1 GTP-Binding Protein / Q000502:physiology*; D018631:ras Proteins / Q000235:genetics*
D018960:Hyaluronan Receptors; D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering; D012795:Sialoglycoproteins; C506896:Spp1 protein, mouse; D053495:Osteopontin; D020830:rac1 GTP-Binding Protein; D018631:ras Proteins